Andanda A P
School of Law, University of the Witwatersrand, South Africa.
Afr J Med Med Sci. 2007;36 Suppl:55-61.
The challenges that most African countries face in an attempt to join the ongoing quest for the development and transfer of the products derived from health biotechnology are threefold: High research costs, inadequate regulatory capacity and unfavourable intellectual property arrangements. It is argued in this paper that these challenges are representative of the legislative and regulatory issues that require proper management in order to enable African countries to focus on the key research areas that are related to the burden of diseases that are prevalent in the region and to harness the products of such research for the benefit of the region. This paper discusses the challenges involved in managing the legislative and regulatory issues in health biotechnology and proposes specific ideas on the way forward for Africa. The methodology used is a review of the manner in which three African countries, Cameroon, Kenya and Nigeria, have encountered and dealt with such regulatory challenges. The review is carried out from policy and legal analysis perspectives.
高昂的研究成本、监管能力不足以及不利的知识产权安排。本文认为,这些挑战代表了立法和监管问题,需要进行妥善管理,以使非洲国家能够专注于与该地区普遍存在的疾病负担相关的关键研究领域,并利用此类研究的产品造福该地区。本文讨论了管理健康生物技术立法和监管问题所涉及的挑战,并就非洲的前进道路提出了具体想法。所采用的方法是对喀麦隆、肯尼亚和尼日利亚这三个非洲国家遇到并应对此类监管挑战的方式进行审查。该审查是从政策和法律分析的角度进行的。